Premaitha Health Plc, which has a prenatal test for assessing the risk of Down’s syndrome and other genetic defects, has raised £8 million from a placement of new shares on the AIM section of the London Stock Exchange. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals